Roivant Sciences Ltd. (ROIV) Discusses FDA Approval of LISRAYA as First Oral Targeted Therapy for Dermatomyositis - Slideshow (NASDAQ:ROIV) 2026-08-30
· seekingalpha.com
2026-08-30. The following slide deck was published by Roivant Sciences Ltd.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...